NASDAQ · ABEO
Healthcare · Biotechnology
$5.11
Down-$0.10 (-1.96%)
Updated Oct 6, 2026, 9:41 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ABEO
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ABEO closed at $5.11 after 20 trading sessions, down 12.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $5.07 | $5.16 | $4.985 | $5.11 | 1.4M |
| Oct 2, 2026 | $5.09 | $5.105 | $4.985 | $5.03 | 1.21M |
| Oct 1, 2026 | $5.22 | $5.25 | $4.985 | $5.01 | 1.48M |
| Sep 30, 2026 | $5.16 | $5.33 | $5.10 | $5.25 | 1.13M |
| Sep 29, 2026 | $5.30 | $5.30 | $5.11 | $5.16 | 1.25M |
| Sep 28, 2026 | $5.35 | $5.40 | $5.19 | $5.29 | 872.88K |
| Sep 25, 2026 | $5.45 | $5.475 | $5.335 | $5.40 | 720.71K |
| Sep 24, 2026 | $5.59 | $5.59 | $5.38 | $5.43 | 852.42K |
| Sep 23, 2026 | $5.82 | $5.90 | $5.52 | $5.53 | 1.19M |
| Sep 22, 2026 | $5.71 | $5.865 | $5.69 | $5.82 | 1.02M |
| Sep 21, 2026 | $5.66 | $5.68 | $5.59 | $5.67 | 1.01M |
| Sep 18, 2026 | $5.82 | $5.84 | $5.525 | $5.57 | 2.77M |
| Sep 17, 2026 | $5.69 | $5.74 | $5.37 | $5.59 | 3.46M |
| Sep 16, 2026 | $5.51 | $5.549 | $5.215 | $5.37 | 1.9M |
| Sep 15, 2026 | $5.42 | $5.56 | $5.32 | $5.47 | 1.93M |
| Sep 14, 2026 | $5.41 | $5.525 | $5.37 | $5.43 | 1.42M |
| Sep 11, 2026 | $5.55 | $5.66 | $5.40 | $5.415 | 1.6M |
| Sep 10, 2026 | $5.70 | $5.70 | $5.31 | $5.48 | 2.29M |
| Sep 9, 2026 | $5.81 | $5.9073 | $5.70 | $5.79 | 1.78M |
| Sep 8, 2026 | $5.935 | $5.995 | $5.81 | $5.85 | 872.57K |
The latest Smart Investors Daily articles mentioning ABEO.
Company
Market Activity
Research & News
ABEO research
Company profile and research snapshot.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | Cantor Fitzgerald | Overweight | — |
| Sep 17, 2026 | Roth Capital | Buy | — |
| Aug 14, 2026 | Oppenheimer | Outperform | — |
| May 28, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 19, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 22, 2026
Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference. Madhav Vasanthavada, Abeona’s senior vice president
Yahoo · Sep 22, 2026
Abeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that the launch requires a
Yahoo · Sep 18, 2026
- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts - - Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families - CLEVELAND, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultrage
Benzinga · Sep 18, 2026
Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ABEO.
